fbpx

Year

2015
Complete (100%) bioavailability after subcutaneous administration when compared with intravenous administration - Diuresis at 8 and 24 hours was equivalent to diuresis following standard intravenous administration - U.S. and EU regulatory filings anticipated in 2016 -LEXINGTON, MA. - scPharmaceuticals, Inc. today announced positive results from its pharmacokinetic and pharmacodynamics phase 3 pivotal registration trial.  The trial in...
GAITHERSBURG, Md., Oct. 22, 2015 /PRNewswire/ -- Vtesse, Inc. announced today the addition of Elizabeth Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurological Sciences and Biochemistry at Rush University Medical Center to its Scientific Advisory Board (SAB) and that Michael Massaro has joined the company as Vice President, Clinical Operations. Today's news comes on the heels of Vtesse's...
CERAMENTT'G Shown to Decrease Infection and Increase New Bone Growth in a Pivotal Animal Model  Lund, Sweden, (PRNEWSWIRE) October 20, 2015 - BONESUPPORTT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced data from the first U.S. study of CERAMENTT with Gentamicin in...
Lundbeck Foundation is investing a further DKK 15 million in Aarhus-based Insusense Therapeutics, a biotech company which develops new drugs for the treatment of type 2 diabetes and obesity.
NEW YORK, Oct. 9, 2015 /PRNewswire-iReach/ -- River Vision Development Corp. (RVDC) today announced the completion of enrollment of a Phase 2 clinical study of RV001 (teprotumumab) for the treatment of Graves' Orbitopathy (GO). RV001 is a fully human IGF-1 receptor antagonist antibody with a safety database comprised of more than 700 cancer patients. The study is being conducted at 15 sites...
Lundbeck Foundation has decided to invest DKK 300 million in Danish biotech companies over the next four years. The funds will be invested by Lundbeckfond Emerge with the aim of generating a portfolio of five active companies over the course of a couple of years.
·         50% Less Fracture Rates with CERAMENTT with Gentamicin·         50% Less Infection Recurrence with CERAMENTT with Gentamicin·         313 Patients Total in All Groups with a Minimum of 1 Year Follow-UpLund, Sweden, (PRNEWSWIRE) October 6, 2015 - BONESUPPORTT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic...
During its first year of operations, Vtesse advances lead program into late-stage, pivotal trial and launches www.theNPCstudy.com- Goal is to establish a clear foundational data set on the safety and efficacy of VTS-270 for treatment of NPCGAITHERSBURG, Md., Sept. 28, 2015 /PRNewswire/ -- Vtesse, Inc. today announced that the first three patients have been screened for inclusion in...
CERAMENTT with Gentamicin Shown to Decrease Recurrence of Infection and Increase Bone FormationLund, Sweden, (PRNEWSWIRE) September 24, 2015 - BONESUPPORTT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the presentation of new clinical data with the Company's platform bone void filler, CERAMENTT...
Lundbeck Foundation and a number of other European Foundations have established a new award for responsible research and innovation.
1 2 3 4 7

News

Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge